NEW YORK (GenomeWeb News) – Myriad Genetics said today that Mammography Reporting Systems, a breast cancer tracking and reporting software service, will use risk markers to identify patients who might benefit from Myriad's BRACAnalysis test.

Myriad said that MRS will incorporate risk factors for hereditary breast cancer risk in its software, enabling more physicians at mammography screening centers to identify patients who may benefit from the Myriad test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.